D Craig Allred
Affiliation: Washington University School of Medicine
- Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24D Craig Allred
National Surgical Adjuvant Breast and Bowel Project, Washington University School of Medicine, Department of Pathology and Immunology, 660 Euclid Campus Box 8118, St Louis, MO 63110, USA
J Clin Oncol 30:1268-73. 2012..Patients were enrolled without knowledge of hormone receptor status. The current study retrospectively evaluated the relationship between receptors and response to tamoxifen...
- An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situFariba Behbod
Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, 3901 Rainbow Blvd, Kansas City, KS 66160, USA
Breast Cancer Res 11:R66. 2009..The resulting models, which mimicked some of the diversity of human noninvasive breast cancers in vivo, were used to show whether subtypes of human DCIS might contain distinct subpopulations of tumor-initiating cells...
- Ductal carcinoma in situ: terminology, classification, and natural historyD Craig Allred
Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8118, St Louis, MO 63110, USA
J Natl Cancer Inst Monogr 2010:134-8. 2010..This article provides a general overview of DCIS, including historical perspective, methods of classification, current perspective, and future goals...
- Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancerD Craig Allred
Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO, USA
Mod Pathol 23:S52-9. 2010..This paper briefly reviews the assessment of ERalpha, PgR, and HER2 in breast cancer, emphasizing recent progress and persistent controversies...
- Molecular biomarkers of risk in premalignancy and breast cancer preventionD Craig Allred
Department of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8118, St Louis, MO 63110, USA
Cancer Prev Res (Phila) 4:1947-52. 2011..Fortunately, there are many other promising biomarkers under investigation, as well as several underutilized experimental strategies which could help promote successful breast cancer prevention...
- The relevance of mouse models to understanding the development and progression of human breast cancerD Craig Allred
Department of Pathology and Immunology, Washington University School of Medicine, Campus Box 8118, 660 South Euclid Avenue, St Louis, MO 63110, USA
J Mammary Gland Biol Neoplasia 13:279-88. 2008..This chapter reviews the historical development of mouse models of breast cancer and highlights some of their major strengths, weaknesses, and contributions...
- Ductal carcinoma in situ and the emergence of diversity during breast cancer evolutionD Craig Allred
Department of Pathology, Washington University School of Medicine, St Louis, MO 63110, USA
Clin Cancer Res 14:370-8. 2008..Human invasive breast cancers (IBC) show enormous histologic and biological diversity. This study comprehensively evaluated diversity in ductal carcinoma in situ (DCIS), the immediate precursors of IBCs...
- Alterations of gene expression in the development of early hyperplastic precursors of breast cancerSangjun Lee
Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO 63110, USA
Am J Pathol 171:252-62. 2007..Because HELUs are such early potential precursors of breast cancer, targeting some of these alterations may be especially promising strategies for breast cancer prevention...
- Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancerSangjun Lee
Departments of Pathology and Immunology, Cell Molecular Biology and Physiology, Medicine, BRIGHT Institute, Biostatistics, and Surgery, Washington University School of Medicine, St Louis, Missouri, USA
Cancer Res 72:4574-86. 2012..Targeting some of these genes may improve the detection, diagnosis, and therapy of DCIS...
- Whole-genome analysis informs breast cancer response to aromatase inhibitionMatthew J Ellis
Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri 63110, USA
Nature 486:353-60. 2012..Prospective clinical trials based on these findings will require comprehensive genome sequencing...
- Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinomaJianzhou Wang
Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
Cancer 94:3107-14. 2002..In this study, the authors investigated the roles of tumor nuclear grade, mitotic activity, and biomarker expression profiles in predicting the pathologic response of breast tumors to preoperative chemotherapy...
- Pathologic Outcomes of Nonmalignant Papillary Breast Lesions Diagnosed at Imaging-guided Core Needle BiopsySusan O Holley
Breast Imaging Division, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S Kingshighway Blvd, Campus Box 8131, St Louis, MO 63110
Radiology 265:379-84. 2012..rsna, 2012...
- Recommendations for validating estrogen and progesterone receptor immunohistochemistry assaysPatrick L Fitzgibbons
Department of Pathology, St Jude Medical Center, Fullerton, California 92835, USA
Arch Pathol Lab Med 134:930-5. 2010....
- Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intMatthew J Ellis
Siteman Cancer Center, Washington University in St Louis, 660 South Euclid Avenue, St Louis, MO 63110, USA
J Clin Oncol 29:2342-9. 2011..To study this treatment option, responses to three AIs were compared in a randomized phase II neoadjuvant trial designed to select agents for phase III investigations...
- Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinomaKelly J Butnor
Department of Pathology, University of Vermont Fletcher Allen Health Care, Burlington, VT 05401, USA
Arch Pathol Lab Med 130:823-7. 2006..Standard panels of immunohistochemical markers are of limited benefit...